Literature DB >> 21341261

A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies.

Nadine Hövelmeyer1, Sonja Reissig, Nguyen Thi Xuan, Petra Adams-Quack, Dominika Lukas, Alexei Nikolaev, Dirk Schlüter, Ari Waisman.   

Abstract

A20/TNFAIP3 is an ubiquitin-editing enzyme, important for the regulation of the NF-κB pathway. Mutations in the TNFAIP3 gene have been linked to different human autoimmune disorders. In human B-cell lymphomas, the inactivation of A20 results in constitutive NF-κB activation. Recent studies demonstrate that in mice the germline inactivation of A20 leads to early lethality, due to inflammation in multiple organs of the body. In this report, we describe a new mouse strain allowing for the tissue-specific deletion of A20. We show that B-cell-specific deletion of A20 results in a dramatic reduction in marginal zone B cells. Furthermore, A20-deficient B cells display a hyperactive phenotype represented by enhanced proliferation upon activation. Finally, these mice develop higher levels of serum immunoglobulins, resulting in an excessive production of self-reactive autoantibodies.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21341261     DOI: 10.1002/eji.201041313

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  49 in total

1.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  A20 edits ubiquitin and autoimmune paradigms.

Authors:  Flavius Martin; Vishva M Dixit
Journal:  Nat Genet       Date:  2011-08-29       Impact factor: 38.330

Review 3.  Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

4.  A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7.

Authors:  Kelly Verhelst; Isabelle Carpentier; Marja Kreike; Laura Meloni; Lynn Verstrepen; Tobias Kensche; Ivan Dikic; Rudi Beyaert
Journal:  EMBO J       Date:  2012-08-28       Impact factor: 11.598

Review 5.  Regulation of nuclear factor-κB in autoimmunity.

Authors:  Shao-Cong Sun; Jae-Hoon Chang; Jin Jin
Journal:  Trends Immunol       Date:  2013-02-20       Impact factor: 16.687

Review 6.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Chandra Mohan; Chaim Putterman
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

Review 7.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

Review 8.  Regulation of NF-κB by deubiquitinases.

Authors:  Edward W Harhaj; Vishva M Dixit
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 9.  A20: linking a complex regulator of ubiquitylation to immunity and human disease.

Authors:  Averil Ma; Barbara A Malynn
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

10.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.